Adial Pharmaceuticals, Inc. Increase (Decrease) in Accrued Liabilities
Adial Pharmaceuticals, Inc. (ADIL) reported Increase (Decrease) in Accrued Liabilities of -$2.35 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-14
- Adial Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was -$2.55M.
- Adial Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was $194.80K, a 139.79% increase year-over-year.
- Adial Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $143.23K, a 18.86% decline year-over-year.
- Adial Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $94.07K, a 43.26% decline year-over-year.
- Adial Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was $100.30K, a 49.78% decline from fiscal 2024.
- Adial Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was $199.71K.
- Adial Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was -$485.58K.
- Adial Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was -$1.41M, a 192.98% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities 12 month | Increase (Decrease) in Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$2.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$2.35M 10-Q · filed 2026-08-14 | -$2.21M derived: sum of 3 quarters · filed 2026-08-14 | -$2.12M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2026-03-31 | $194.80K 10-Q · filed 2026-05-08 | $338.03K derived: sum of 2 quarters · filed 2026-05-08 | $432.10K derived: sum of 3 quarters · filed 2026-05-08 | $213.86K derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-12-31 | $143.23K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $237.30K derived: sum of 2 quarters · filed 2026-03-05 | $19.06K derived: sum of 3 quarters · filed 2026-08-14 | $100.30K 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $94.07K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$124.17K derived: sum of 2 quarters · filed 2026-08-14 | -$42.93K 10-Q · filed 2025-11-13 | $133.59K derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-06-30 | -$218.24K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$137.00K 10-Q · filed 2026-08-14 | -$137.55K 10-Q · filed 2025-08-13 | $39.53K derived: sum of 3 quarters · filed 2026-08-14 | $205.30K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $81.24K 10-Q · filed 2026-05-08 | $257.77K derived: sum of 2 quarters · filed 2026-05-08 | $423.54K derived: sum of 3 quarters · filed 2026-05-08 | $383.43K derived: sum of 4 quarters · filed 2026-05-08 | |||
| 2024-12-31 | $176.53K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $342.30K derived: sum of 2 quarters · filed 2026-03-05 | $302.19K derived: sum of 3 quarters · filed 2026-03-05 | $199.71K 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $165.77K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $125.67K derived: sum of 2 quarters · filed 2025-11-13 | $23.18K 10-Q · filed 2025-11-13 | $92.31K derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | -$40.11K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$142.59K 10-Q · filed 2025-08-13 | -$73.46K derived: sum of 3 quarters · filed 2025-08-13 | $10.74K derived: sum of 4 quarters · filed 2025-08-13 | |||
| 2024-03-31 | -$102.48K 10-Q · filed 2025-05-14 | -$33.35K derived: sum of 2 quarters · filed 2025-05-14 | $50.85K derived: sum of 3 quarters · filed 2025-05-14 | -$610.84K derived: sum of 4 quarters · filed 2025-05-14 | |||
| 2023-12-31 | $69.13K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $153.34K derived: sum of 2 quarters · filed 2025-03-04 | -$508.35K derived: sum of 3 quarters · filed 2025-03-04 | -$485.58K 10-K · filed 2025-03-04 | |||
| 2023-09-30 | $84.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$577.49K derived: sum of 2 quarters · filed 2024-11-13 | -$554.71K 10-Q · filed 2024-11-13 | -$444.63K derived: sum of 4 quarters · filed 2024-11-13 | |||
| 2023-06-30 | -$661.69K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$638.92K 10-Q · filed 2024-08-13 | -$528.83K derived: sum of 3 quarters · filed 2024-08-13 | -$595.44K derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-03-31 | $22.77K 10-Q · filed 2023-05-12 | $132.85K derived: sum of 2 quarters · filed 2024-04-01 | $66.25K derived: sum of 3 quarters · filed 2024-04-01 | -$708.73K derived: sum of 4 quarters · filed 2024-04-01 | |||
| 2022-12-31 | $110.08K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $43.47K derived: sum of 2 quarters · filed 2024-04-01 | -$731.50K derived: sum of 3 quarters · filed 2024-04-01 | -$1.41M 10-K · filed 2024-04-01 | -$1.22M 10-K · filed 2023-03-30 | ||
| 2022-09-30 | -$66.61K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-11-14 | -$841.59K derived: sum of 2 quarters · filed 2023-11-14 | -$1.52M 10-Q · filed 2023-11-14 | -$1.42M 10-Q · filed 2022-11-14 | -$871.59K derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | -$774.98K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2023-10-30 | -$1.46M 10-Q/A · filed 2023-10-30 | -$1.37M 10-Q · filed 2022-08-15 | -$804.99K derived: sum of 3 quarters · filed 2023-10-30 | -$769.87K derived: sum of 4 quarters · filed 2023-10-30 | ||
| 2022-03-31 | -$682.10K 10-Q · filed 2023-05-12 | -$30.01K derived: sum of 2 quarters · filed 2023-05-12 | $5.11K derived: sum of 3 quarters · filed 2023-05-12 | $363.38K derived: sum of 4 quarters · filed 2023-05-12 | |||
| 2021-12-31 | $652.09K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $687.21K derived: sum of 2 quarters · filed 2023-03-30 | $1.05M derived: sum of 3 quarters · filed 2023-03-30 | $1.52M 10-K · filed 2023-03-30 | |||
| 2021-09-30 | $35.12K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $393.39K derived: sum of 2 quarters · filed 2022-11-14 | $868.20K 10-Q · filed 2022-11-14 | $712.99K derived: sum of 4 quarters · filed 2022-11-14 | |||
| 2021-06-30 | $358.27K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $833.09K 10-Q · filed 2022-08-15 | $677.87K derived: sum of 3 quarters · filed 2022-08-15 | $1.28M derived: sum of 4 quarters · filed 2022-08-15 | |||
| 2021-03-31 | $474.81K 10-Q · filed 2022-05-16 | $319.60K derived: sum of 2 quarters · filed 2022-05-16 | $925.67K derived: sum of 3 quarters · filed 2022-05-16 | $971.74K derived: sum of 4 quarters · filed 2022-05-16 | |||
| 2020-12-31 | -$155.21K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $450.86K derived: sum of 2 quarters · filed 2022-03-28 | $496.93K derived: sum of 3 quarters · filed 2022-03-28 | $458.54K 10-K · filed 2022-03-28 | $624.79K 10-K · filed 2021-03-22 | ||
| 2020-09-30 | $606.08K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $652.15K derived: sum of 2 quarters · filed 2021-11-15 | $613.75K 10-Q · filed 2021-11-15 | $670.30K derived: sum of 4 quarters · filed 2021-11-15 | |||
| 2020-06-30 | $46.07K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $7.67K 10-Q · filed 2021-08-12 | $64.22K derived: sum of 3 quarters · filed 2021-08-12 | -$93.85K derived: sum of 4 quarters · filed 2021-08-12 | |||
| 2020-03-31 | -$38.40K 10-Q · filed 2021-05-17 | $18.15K derived: sum of 2 quarters · filed 2021-05-17 | -$139.92K derived: sum of 3 quarters · filed 2021-05-17 | $41.51K derived: sum of 4 quarters · filed 2021-05-17 | |||
| 2019-12-31 | $56.55K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22 | -$101.52K derived: sum of 2 quarters · filed 2021-03-22 | $79.91K derived: sum of 3 quarters · filed 2021-03-22 | $190.54K 10-K · filed 2021-03-22 | |||
| 2019-09-30 | -$158.07K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $23.36K derived: sum of 2 quarters · filed 2020-11-13 | $134.00K 10-Q · filed 2020-11-13 | ||||
| 2019-06-30 | $181.43K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $292.06K 10-Q · filed 2020-08-13 | |||||
| 2019-03-31 | $110.63K 10-Q · filed 2020-05-14 | ||||||
| 2018-12-31 | $155.74K 10-K · filed 2020-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |